ArticleBreast cancer research and treatment2026
Characteristics, treatment and survival in de novo and metachronous metastatic breast cancer: a nationwide comparative analysis.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare patient characteristics, treatment patterns, and survival between de novo and metachronous metastatic breast cancer (MBC) using nationwide data.
methodsA total of 2,366 MBC patients (900 de novo, 1,466 metachronous) diagnosed in 2019 were selected from the Netherlands Cancer Registry. Patient- and tumor characteristics and systemic treatment patterns were compared using chi-squared or Fisher's exact tests. Overall survival (OS) was compared using Kaplan-Meier curves and Cox proportional hazard analyses. All analyses were stratified by clinical subtype (HR+/HER2-, HR+/HER2+, HR-/HER2+, HR-/HER2-). For patients with HR+/HER2 - tumors, a sub-analysis examined OS in de novo versus metachronous MBC, stratifying the latter by receipt of prior (neo)adjuvant systemic treatment.
resultsDe novo MBC patients were younger, had more HER2-positive (22% vs. 11%) and fewer triple-negative tumors (11% vs. 16%). Patients with metachronous MBC more often had CNS metastases and metastases in other localizations than the lymph nodes, bone, visceral organs and CNS. Among HER2 + patients, chemotherapy and targeted therapy were more often administered in de novo versus metachronous MBC. Median OS was longer in de novo MBC for HR+/HER2- tumors (40.8 vs. 30.3 months, aHR 1.27, 95%CI 1.12-1.43) and HR-/HER2 + tumors (51.1 vs. 9.1 months, aHR 1.62, 95%CI 1.03-2.54). In HR+/HER2 - patients, metachronous MBC patients who received prior (neo)adjuvant systemic treatment had worse OS than de novo cases (prior chemotherapy: aHR 1.52, 95%CI 1.29-1.78); prior hormonal therapy only: aHR 1.33, 95%CI 1.10-1.61), whereas those without prior systemic treatment had similar outcomes.
conclusionDe novo and metachronous MBC have different tumor biology, treatment patterns, and survival. In metachronous MBC patients, prior (neo)adjuvant systemic treatment was associated with worse survival compared to de novo MBC or patients with metachronous MBC without prior (neo)adjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.